SBIR/STTR Research Award

Emulsan-based Drug Delivery Devices

Award identifier 549540c6eee6c38e214aa2482b97f691b8f56bfdc47a18814a44b12c09915850Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Immunosaccharide Technologies, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Emulsans are a novel family of functionalized polysaccharides that can be extensively modified structurally leading to substantive changes in solution properties (emulsification) and biological responses in vitro (i.e., macrophage activation, TNF release) and in vivo (i.e., vaccine delivery). In addition, these polymers are 'natural' carriers of other macromolecules with high loading capacities (up to 23 wt %). Based on these features, our hypothesis for the proposed study is that structural analogs of these microbial exopolysaccharides, emulsans, can serve as novel drug delivery vehicles when formed into microparticles with alginate. The powerful combination of significant ligand binding capacity of these polymers, strong structural tailorability and native amphiphilicity (hydrophobic fatty acid side chains, hydrophilic polysaccharide main chain) will allow for exploration of drug delivery vehicles with unique properties. We know of no similar set of relevant properties available with other biomaterials being considered for drug delivery. We plan to use the highly selective biological routes presented in our preliminary data to prepare a group of well-defined emulsan structural analogs. This arsenal of 'structurally tailored' emulsans will then be used to demonstrate the efficacy of these polymers in microparticle format to bind high concentrations of protein and non-protein pharmaceutical compounds, and the ability of said particles to deliver the test compounds to an appropriate cell type. The proposed studies will provide the first indication of the efficacy of emulsan structural analogs as drug delivery vehicles. Furthermore, lead candidates will result from the study in preparation for future studies in vitro and in vivo of mechanism, optimization of delivery and targeting, and overall efficacy. This new direction builds off of our extensive understanding of physiological and genetic control of emulsan biosynthesis, as well as initial insight into cell interactions related to cytokine control.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.